CASI - CASIファ―マシュ―ティカルズ （CASI Pharmaceuticals Inc.） CASIファ―マシュ―ティカルズCASIのチャート
CASIの企業情報
| symbol | CASI |
|---|---|
| 会社名 | CASI Pharmaceuticals Inc. （CASIファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エントレメッド（EntreMed Inc.）は臨床段階の医薬品会社。同社の薬品候補「ENMD-2076」はがん治療用のオーロラAと血管新生キナーゼ阻害剤である。「ENMD-2076」は進行性固形腫瘍、多発性骨髄腫、白血病の患者での第I相試験を完了した、プラチナ抵抗性再発卵巣癌の患者での多施設共同第II相試験を行うためにデータを完了している。同社のほかの薬品候補は関節リウマチの治療用の「2-methoxyestrdiol」(2ME2 Panzem)、「ENMD-1198」及び「MKC-1」を含む。「ENMD-2076」は新規経口で有効な、オーロラAと血管新生キナーゼ阻害剤であり、癌や炎症性疾患にリンクされるオーロラAおよび複数のチロシンキナーゼに対して強力な活性を有する。 CASIファ―マシュ―ティカルズは、米国の製薬会社。癌および他の疾患の治療薬を開発する。臨床段階にある主要な医療薬候補は、癌治療のオ―ロラAと血管新生キナ―ゼ阻害剤「ENMD-2076」である。そのほか、慢性関節リウマチ治療の経口活性化合物「2-methoxyestrdiol」と経口活性小分子の細胞周期阻害剤「MKC-1」を開発する。 CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China. |
| 本社所在地 | 9620 Medical Center Drive Suite 300 Rockville MD 20850 USA |
| 代表者氏名 | Wei-Wu He 魏偉 |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 240-864-2600 |
| 設立年月日 | 33482 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 50人 |
| url | www.casipharmaceuticals.com |
| nasdaq_url | https://www.nasdaq.com/symbol/casi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.27928 |
| 終値（lastsale） | 3.78 |
| 時価総額（marketcap） | 327314921.22 |
| 時価総額 | 時価総額（百万ドル） 284.01930 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 218.08174 |
| 当期純利益 | 当期純利益（百万ドル） -16.11213 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 CASI Pharmaceuticals Inc revenues was not reported. Net loss increased from $4.1M to $9.5M. Higher net loss reflects General and administrative - Gross increase from $1.2M to $5.2M (expense) Research and development -Gross increase of 25% to $3.3M (expense) Change in fair value of contingent right decrease from $3K (income) to $0K. |
CASIのテクニカル分析
CASIのニュース
CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying 2022/08/29 12:58:47 Benzinga
The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 CASI Pharmaceuticals The Trade: CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) Director James Huang bought a total of 44,527 shares at an average price of $3.75. To … Full story available on Benzinga.com
CASI Pharmaceuticals Inc. (NASDAQ: CASI) Stock Could Make A -980.25% Loss 2022/08/17 13:00:00 Marketing Sentinel
In the last trading session, 1.37 million CASI Pharmaceuticals Inc. (NASDAQ:CASI) shares changed hands as the company’s beta touched 0.66. With the company’s per share price at $3.24 changed hands at -$0.78 or -19.40% during last session, the market valuation stood at $49.44M. CASI’s last price was a discount, traded about -437.04% off its 52-week … CASI Pharmaceuticals Inc. (NASDAQ: CASI) Stock Could Make A -980.25% Loss Read More »
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript 2022/08/12 16:28:12 Seeking Alpha
CASI Pharmaceuticals, Inc. (NASDAQ:NASDAQ:CASI) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Wei Zhang – Vice President Wei-Wu He – Chairman and Chief…
CASI Pharmaceuticals Inc. (NASDAQ:CASI) Share Price Recovers 42.56% From Its Lows, But Can It Maintain Its Rise? 2022/08/12 11:30:00 Marketing Sentinel
In last trading session, CASI Pharmaceuticals Inc. (NASDAQ:CASI) saw 5.14 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $3.90 trading at $0.89 or 29.57% at ring of the bell on the day assigns it a market valuation of $52.42M. That closing price of CASI’s stock is … CASI Pharmaceuticals Inc. (NASDAQ:CASI) Share Price Recovers 42.56% From Its Lows, But Can It Maintain Its Rise? Read More »
Recap: CASI Pharmaceuticals Q2 Earnings 2022/08/12 11:21:14 Benzinga
CASI Pharmaceuticals (NASDAQ: CASI ) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings CASI Pharmaceuticals beat estimated earnings by 12.5%, reporting an EPS of $-0.56 versus … Full story available on Benzinga.com
CASI CEO Buys Shares in the Company; Street Sees Over 11X Upside 2022/06/20 12:41:11 TipRanks
In a challenging market environment, positive insider moves help shore up investor sentiment in a stock. This is exactly the case for biopharmaceutical company CASI Pharmaceuticals, Inc. (CASI), whose CEO just bought a sizable chunk of this penny stock. CASI is focused on progressing its hematology-oncology therapeutic portfolio and aims to be a leader in the Greater China market. Its shares have dropped nearly 65% so far in 2022, and the company had to undertake a 1-for-10 reverse stock split on June 1 to remain compliant with NASDAQ’s minimum bid price requirement. As a result of this maneuver, the company now has about 13.
Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today? 2022/06/02 14:44:24 InvestorPlace
CASI Pharmaceuticals (CASI) stock rocketed higher in pre-market trading this morning but it''s not due to any positive news from the company.
CASI Pharmaceuticals stock falls after reverse split takes effect 2022/06/02 10:34:34 MarketWatch
Shares of CASI Pharmaceuticals Inc. are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a big gain for the Maryland-based biopharmaceutical company''s stock, closed Wednesday at a pre-split price of 40.63 cents, meaning a 1-for-10 reverse split would adjust the price to $4.063. The stock is currently trading 15.6% below that split-adjusted price. On a pre-split basis, the stock has closed below $1 since Nov. 16, 2021. Through Wednesday, the stock had plunged 94.9% year to date, while the iShares Biotechnology ETF has dropped 24.4% and the S&P 500 has lost 14.0%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
44 Stocks Moving In Wednesday''s Mid-Day Session 2022/06/01 16:14:08 Benzinga
Gainers Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) shares jumped 63.9% to $3.9990 after the company announced the USPTO issued a patent to the company titled "Synthetic Chimeric Poxviruses." After the market closed on Tuesday, Tonix also announced a $12.5 million share repurchase program. Helius Medical Technologies, Inc. (NASDAQ: HSDT ) gained 58% to $2.32. Helius Medical Technologies announced the launch of patient therapy access program for Portable Neuromodulation Stimulator. vTv Therapeutics Inc. (NASDAQ: VTVT ) rose 39% to $0.7701 after the company announced entry into agreements that include a $25 million investment by G42 Investments. View, Inc. (NASDAQ: VIEW ) jumped 28% to $1.6250 as the company reported a rise in FY21 sales. Spark Networks SE (NASDAQ: LOV ) gained 27% to $2.68 after the company announced initiation of exploration of strategic alternatives. CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) jumped 26.3% to $0.4350. Casi Pharmaceuticals recently announced a 1-for-10 reverse stock split effective June 1.
CASI Pharmaceuticals up 42% premarket ahead of reverse stock split (NASDAQ:CASI) 2022/06/01 13:17:13 Seeking Alpha
Shares of microcap CASI Pharmaceuticals (CASI) are up 42% in premarket trading ahead of a 1-for-10 reverse stock split that becomes effective at 5p ET.
Why Is CASI Pharmaceuticals (CASI) Stock Up 700% Today? 2022/06/02 14:44:24 InvestorPlace
CASI Pharmaceuticals (CASI) stock rocketed higher in pre-market trading this morning but it''s not due to any positive news from the company.
CASI Pharmaceuticals stock falls after reverse split takes effect 2022/06/02 10:34:34 MarketWatch
Shares of CASI Pharmaceuticals Inc. are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a big gain for the Maryland-based biopharmaceutical company''s stock, closed Wednesday at a pre-split price of 40.63 cents, meaning a 1-for-10 reverse split would adjust the price to $4.063. The stock is currently trading 15.6% below that split-adjusted price. On a pre-split basis, the stock has closed below $1 since Nov. 16, 2021. Through Wednesday, the stock had plunged 94.9% year to date, while the iShares Biotechnology ETF has dropped 24.4% and the S&P 500 has lost 14.0%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
44 Stocks Moving In Wednesday''s Mid-Day Session 2022/06/01 16:14:08 Benzinga
Gainers Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) shares jumped 63.9% to $3.9990 after the company announced the USPTO issued a patent to the company titled "Synthetic Chimeric Poxviruses." After the market closed on Tuesday, Tonix also announced a $12.5 million share repurchase program. Helius Medical Technologies, Inc. (NASDAQ: HSDT ) gained 58% to $2.32. Helius Medical Technologies announced the launch of patient therapy access program for Portable Neuromodulation Stimulator. vTv Therapeutics Inc. (NASDAQ: VTVT ) rose 39% to $0.7701 after the company announced entry into agreements that include a $25 million investment by G42 Investments. View, Inc. (NASDAQ: VIEW ) jumped 28% to $1.6250 as the company reported a rise in FY21 sales. Spark Networks SE (NASDAQ: LOV ) gained 27% to $2.68 after the company announced initiation of exploration of strategic alternatives. CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) jumped 26.3% to $0.4350. Casi Pharmaceuticals recently announced a 1-for-10 reverse stock split effective June 1.
CASI Pharmaceuticals up 42% premarket ahead of reverse stock split (NASDAQ:CASI) 2022/06/01 13:17:13 Seeking Alpha
Shares of microcap CASI Pharmaceuticals (CASI) are up 42% in premarket trading ahead of a 1-for-10 reverse stock split that becomes effective at 5p ET.
Now Is The Time To Build A Position In CASI Pharmaceuticals Inc. (NASDAQ:CASI) 2022/05/27 14:00:00 Marketing Sentinel
CASI Pharmaceuticals Inc. (NASDAQ:CASI)’s traded shares stood at 2.31 million during the last session, with the company’s beta value hitting 0.70. At the close of trading, the stock’s price was $0.52, to imply an increase of 11.56% or $0.05 in intraday trading. The CASI share’s 52-week high remains $1.77, putting it -240.38% down since that … Now Is The Time To Build A Position In CASI Pharmaceuticals Inc. (NASDAQ:CASI) Read More »